Deep Parikh, MD, sat down with Emily Kaiser Maharjan from Optometry Times to talk about his presentation at Collaborative Care Symposium on advanced treatments in neovascular retinal disease.

I live with lacrimal gland failure, corneal neuralgia, and meibomian gland dysfunction—also known as dry eye. These diseases ...

The FDA has approved Tryptyr (acoltremon) as the first TRPM8-targeting eye drop for dry eye disease, stimulating natural tear ...

Early improvements in OSDI scores and tear osmolarity reinforce lifitegrast’s role in managing inflammation-driven dry eye ...

The active ingredient in Tryptyr is acoltremon, an agonist of transient receptor potential melastatin 8 thermoreceptors.

To accomplish this, a retrospective case series study was conducted involving 76 patients previously diagnosed with dry eye and exhibiting unsatisfactory responses to various prior clinical treatments ...

Alcon, a global eye care company known for products such as Systane and GenTeal Tears, plans to launch Tryptyr in the U.S.

In this episode of CT BUZZ, Reporter Jillian Andrews sat down with Dr. Donald Higgins, Optometrist and Medical Director of ...

Spun off from Novartis in 2019, Alcon is betting on new product launches to accelerate sales growth in the second half of ...

Porter Ophthalmology has released an informative new article addressing a frequently overlooked but critical topic in LASIK ...

In this Healio Video Exclusive, Trevor Angell, MD, speaks with Vivek R. Patel, MD, about how endocrinologists and ...